- Home
- ADXN vs OSRH Comparison
ADXN vs OSRH Comparison
Compare ADXN & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADXN | OSRH |
|---|---|---|
| Founded | 2002 | N/A |
| Country | Switzerland | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 12.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ADXN | OSRH |
|---|---|---|
| Price | $8.23 | $0.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.1K | ★ 11.7M |
| Earning Date | 12-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $198,824.00 | N/A |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.51 | $0.45 |
| 52 Week High | $12.05 | $12.54 |
Technical Indicators
Market Signals| Indicator | ADXN | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 54.57 |
| Support Level | $7.59 | $0.67 |
| Resistance Level | $8.99 | $0.76 |
| Average True Range (ATR) | 0.52 | 0.10 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 50.97 | 54.93 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About OSRH OSR Holdings Inc. Common Stock
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.